Franziska Hutter
study nurse
Medizinische Onkologie und Hämatologie · Dept. I
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Aug 16, 2024
Clinical Studies - Aug 16, 2024 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Hutter Franziska, Quinter Janine
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Mar 28, 2024
Clinical Studies - Mar 28, 2024 - Dec 31, 2099
Ongoing
Project leader: Hess Dagmar
Members: Hutter Franziska, Quinter Janine
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line chemotherapy (DeLLphi-304)
Jul 17, 2023
Clinical Studies - Jul 17, 2023 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Hutter Franziska, Quinter Janine
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
Jun 21, 2023Das primäre Ziel dieser Studie ist die Charakterisierung des Sicherheitsprofils von BMS-986408 als Monotherapie und in Kombination mit Nivolumab oder Nivolumab und Ipilimumab, um die maximal verträgliche Dosis (MTD) zu ermitteln. Außerdem soll die em...
Clinical Studies - Jun 21, 2023 - Dec 31, 2030
Ongoing
Project leader: Jörger Markus
Members: Hutter Franziska
BMS CA099-003
Jun 21, 2023A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
Clinical Studies - Jun 21, 2023 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Hutter Franziska, Müller Fiona
A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma
Jan 23, 2023Im Rahmen dieser Studie soll untersucht werden, wie si-cher und wirksam das Prüfpräparat ANV419 ist, wenn es allein und in Kombination mit Daratumumab oder mit Lenalidomid plus niedrig dosiertem Dexamethason (Medi-kamente, die bereits für die Behandl...
Clinical Studies - Jan 23, 2023 - Dec 31, 2025
Aborted
Project leader: Hess Dagmar
Members: Hutter Franziska
in Subjects with Methylthioadenosine
Oct 8, 2021
Clinical Studies - Oct 8, 2021 - Jan 8, 2025
Completed
Project leader: Schittenhelm Marcus
Members: Hutter Franziska, Quinter Janine
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD - L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III ( N2) non -small cell lung cacner (NSCLC)
Apr 29, 2020Evaluation einer immunmodulatorischen neoadjuvanten Radiotherapie in verschiedenen Dosen nach neoadjuvanter Chemotherapie mit Cisplatin und Docetaxel bei Patienten mit operablem, lokal fortgeschrittenem (Stadium IIIA) Nicht-Kleinzelligen Bronchialkar...
Clinical Studies - Apr 29, 2020 - Aug 24, 2030
Ongoing
Project leader: Früh Martin
Members: Hutter Franziska, Müller Fiona
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic HormoneSensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Mar 3, 2020While many men diagnosed with locally confined disease may be treated definitively with radiation or surgery, ap-proximately 30% of men have recurrent disease and go on to develop metastatic prostate cancer. In addition, 5% to 30% of men with prostat...
Clinical Studies - Mar 3, 2020 - Dec 23, 2024
Completed
Project leader: Fischer Stefanie
Members: Hutter Franziska, Quinter Janine
A phase I/Ib, open-label, multi-center dose escalation study of NIS793 in combination with PDR001 in adult patients with advanced malignancies (CNIS793X2101)
Sep 9, 2019This is a first-in-human (FIH), open label, phase I/Ib, multi-center study which consists of: - a dose escalation part of NIS793 as single agent and in combination with PDR001. Patients treated with NIS793 single agent will switch to NIS793 in comb...
Clinical Studies - Sep 9, 2019 - Oct 18, 2024
Completed
Project leader: Horber Daniel
Members: Müller Fiona, Hutter Franziska
BMS CA027-002
Apr 15, 2019A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers.
Clinical Studies - Apr 15, 2019 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Hutter Franziska, Müller Fiona
MK-3475-054
Feb 15, 2016Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group.
Clinical Studies - Feb 15, 2016 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Hutter Franziska, Müller Fiona